The Partnership for Part D Access is a collection of healthcare stakeholders, including patient groups, advocacy organizations and allied members of industry, who are committed to maintaining beneficiary access to the full range of available medications under Medicare Part D. We represent and care about individuals who would be negatively impacted by changes to Medicare's "protected classes" policy. If changes to the policy were to go forward, it would directly, and negatively, impact persons with mental health conditions, epilepsy, Parkinson’s Disease, lupus, HIV/AIDS, cancer, and those needing organ transplants.
Our Goals
Coordinate the efforts of affected patients and their allies to address this threat to Medicare beneficiary access to the most appropriate medications.
Educate federal policy makers on the history, rationale and importance of maintaining protected status for anticonvulsants, antidepressants, antineoplastics, antipsychotics, antiretrovirals, and immunosuppressants in Part D as part of the “Six Protected Classes.”
Implement effective advocacy and communications strategies to protect consumer access to the Six Protected Classes under Medicare Part D.
